Long-Term Outcome After Antiviral Therapy of Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis

Angelo Iacobellis, Francesco Perri, Maria Rosa Valvano, Nazario Caruso, Grazia Anna Niro, Angelo Andriulli

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background & Aims: We evaluated the long-term outcomes after antiviral therapy of patients with decompensated cirrhosis and hepatitis C virus (HCV) infection. Methods: Seventy-five patients with HCV infection and decompensated cirrhosis received therapy with peginterferon alfa-2b and ribavirin. We compared adverse-event profiles and mortality rates between patients with or without sustained virologic responses (SVRs). The mean follow-up time off therapy was 51 ± 18 months (range, 3-78 months). Results: Seven patients with HCV genotypes 1 or 4 (16%) and 17 patients with genotypes 2 or 3 (55%) achieved SVRs. The mean survival times were 53 months among patients who did not achieve SVRs (95% confidence interval [CI], 48-59 months) and 73 months among those who did achieve SVRs (95% CI, 67-80 months) (P = .004). During the study, 25 patients died (2 with and 23 without SVRs). During the follow-up period, 8 of 24 patients with SVRs (33.3%) and 49 of 51 without SVRs (96.1%) experienced further events of decompensation (P <.0001). The hospital readmission rates for patients with and without SVRs were 7.4 and 56 per 1000 person-months, respectively (ratio of 7.5 without/with SVR; 95% CI, 4.0-16.0; P <.0001). At the end of the follow-up period, the incidence of hepatocellular carcinoma was not associated with clearance of HCV. Conclusions: Among patients with cirrhosis that is a result of HCV infection and who have progressed to a stage of liver decompensation, an SVR after antiviral therapy is a positive prognostic factor.

Original languageEnglish
Pages (from-to)249-253
Number of pages5
JournalClinical Gastroenterology and Hepatology
Volume9
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Virus Diseases
Hepacivirus
Antiviral Agents
Fibrosis
Therapeutics
Confidence Intervals
Genotype
Sustained Virologic Response
Patient Readmission
Ribavirin
Hepatocellular Carcinoma
Survival Rate
Mortality
Liver
Incidence

Keywords

  • Chronic Hepatitis
  • Clinical Trial
  • Liver Disease
  • Peg-IFN

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Long-Term Outcome After Antiviral Therapy of Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis. / Iacobellis, Angelo; Perri, Francesco; Valvano, Maria Rosa; Caruso, Nazario; Niro, Grazia Anna; Andriulli, Angelo.

In: Clinical Gastroenterology and Hepatology, Vol. 9, No. 3, 03.2011, p. 249-253.

Research output: Contribution to journalArticle

@article{5d4a1f716df04f7893a8b79fc5c82446,
title = "Long-Term Outcome After Antiviral Therapy of Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis",
abstract = "Background & Aims: We evaluated the long-term outcomes after antiviral therapy of patients with decompensated cirrhosis and hepatitis C virus (HCV) infection. Methods: Seventy-five patients with HCV infection and decompensated cirrhosis received therapy with peginterferon alfa-2b and ribavirin. We compared adverse-event profiles and mortality rates between patients with or without sustained virologic responses (SVRs). The mean follow-up time off therapy was 51 ± 18 months (range, 3-78 months). Results: Seven patients with HCV genotypes 1 or 4 (16{\%}) and 17 patients with genotypes 2 or 3 (55{\%}) achieved SVRs. The mean survival times were 53 months among patients who did not achieve SVRs (95{\%} confidence interval [CI], 48-59 months) and 73 months among those who did achieve SVRs (95{\%} CI, 67-80 months) (P = .004). During the study, 25 patients died (2 with and 23 without SVRs). During the follow-up period, 8 of 24 patients with SVRs (33.3{\%}) and 49 of 51 without SVRs (96.1{\%}) experienced further events of decompensation (P <.0001). The hospital readmission rates for patients with and without SVRs were 7.4 and 56 per 1000 person-months, respectively (ratio of 7.5 without/with SVR; 95{\%} CI, 4.0-16.0; P <.0001). At the end of the follow-up period, the incidence of hepatocellular carcinoma was not associated with clearance of HCV. Conclusions: Among patients with cirrhosis that is a result of HCV infection and who have progressed to a stage of liver decompensation, an SVR after antiviral therapy is a positive prognostic factor.",
keywords = "Chronic Hepatitis, Clinical Trial, Liver Disease, Peg-IFN",
author = "Angelo Iacobellis and Francesco Perri and Valvano, {Maria Rosa} and Nazario Caruso and Niro, {Grazia Anna} and Angelo Andriulli",
year = "2011",
month = "3",
doi = "10.1016/j.cgh.2010.10.036",
language = "English",
volume = "9",
pages = "249--253",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Long-Term Outcome After Antiviral Therapy of Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis

AU - Iacobellis, Angelo

AU - Perri, Francesco

AU - Valvano, Maria Rosa

AU - Caruso, Nazario

AU - Niro, Grazia Anna

AU - Andriulli, Angelo

PY - 2011/3

Y1 - 2011/3

N2 - Background & Aims: We evaluated the long-term outcomes after antiviral therapy of patients with decompensated cirrhosis and hepatitis C virus (HCV) infection. Methods: Seventy-five patients with HCV infection and decompensated cirrhosis received therapy with peginterferon alfa-2b and ribavirin. We compared adverse-event profiles and mortality rates between patients with or without sustained virologic responses (SVRs). The mean follow-up time off therapy was 51 ± 18 months (range, 3-78 months). Results: Seven patients with HCV genotypes 1 or 4 (16%) and 17 patients with genotypes 2 or 3 (55%) achieved SVRs. The mean survival times were 53 months among patients who did not achieve SVRs (95% confidence interval [CI], 48-59 months) and 73 months among those who did achieve SVRs (95% CI, 67-80 months) (P = .004). During the study, 25 patients died (2 with and 23 without SVRs). During the follow-up period, 8 of 24 patients with SVRs (33.3%) and 49 of 51 without SVRs (96.1%) experienced further events of decompensation (P <.0001). The hospital readmission rates for patients with and without SVRs were 7.4 and 56 per 1000 person-months, respectively (ratio of 7.5 without/with SVR; 95% CI, 4.0-16.0; P <.0001). At the end of the follow-up period, the incidence of hepatocellular carcinoma was not associated with clearance of HCV. Conclusions: Among patients with cirrhosis that is a result of HCV infection and who have progressed to a stage of liver decompensation, an SVR after antiviral therapy is a positive prognostic factor.

AB - Background & Aims: We evaluated the long-term outcomes after antiviral therapy of patients with decompensated cirrhosis and hepatitis C virus (HCV) infection. Methods: Seventy-five patients with HCV infection and decompensated cirrhosis received therapy with peginterferon alfa-2b and ribavirin. We compared adverse-event profiles and mortality rates between patients with or without sustained virologic responses (SVRs). The mean follow-up time off therapy was 51 ± 18 months (range, 3-78 months). Results: Seven patients with HCV genotypes 1 or 4 (16%) and 17 patients with genotypes 2 or 3 (55%) achieved SVRs. The mean survival times were 53 months among patients who did not achieve SVRs (95% confidence interval [CI], 48-59 months) and 73 months among those who did achieve SVRs (95% CI, 67-80 months) (P = .004). During the study, 25 patients died (2 with and 23 without SVRs). During the follow-up period, 8 of 24 patients with SVRs (33.3%) and 49 of 51 without SVRs (96.1%) experienced further events of decompensation (P <.0001). The hospital readmission rates for patients with and without SVRs were 7.4 and 56 per 1000 person-months, respectively (ratio of 7.5 without/with SVR; 95% CI, 4.0-16.0; P <.0001). At the end of the follow-up period, the incidence of hepatocellular carcinoma was not associated with clearance of HCV. Conclusions: Among patients with cirrhosis that is a result of HCV infection and who have progressed to a stage of liver decompensation, an SVR after antiviral therapy is a positive prognostic factor.

KW - Chronic Hepatitis

KW - Clinical Trial

KW - Liver Disease

KW - Peg-IFN

UR - http://www.scopus.com/inward/record.url?scp=79951704255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951704255&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2010.10.036

DO - 10.1016/j.cgh.2010.10.036

M3 - Article

VL - 9

SP - 249

EP - 253

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 3

ER -